Norgestrel
Lo/ovral, Low-ogestrel, Ogestrel, Opill, Ovral (norgestrel) is a small molecule pharmaceutical. Norgestrel was first approved as Lo/ovral on 1982-01-01. The pharmaceutical is active against progesterone receptor.
Download report
Favorite
Searched
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ethinyl estradiol
+
Norgestrel
Norgestrel
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| OPILL | HRA Pharma | N-017031 DISCN | 1982-01-01 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cryselle | ANDA | 2023-06-07 |
| elinest | ANDA | 2018-11-26 |
| low-ogestrel | ANDA | 2023-06-07 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
— G03: Sex hormones and modulators of the genital system
— G03A: Hormonal contraceptives for systemic use
— G03AA: Progestogens and estrogen systemic contraceptives, fixed combinations
— G03AA06: Norgestrel and ethinylestradiol
— G03F: Progestogens and estrogens in combination
— G03FA: Progestogens and estrogens, fixed combinations
— G03FA10: Norgestrel and estrogen
— G03FB: Progestogens and estrogens, sequential preparations
— G03FB01: Norgestrel and estrogen
HCPCS
Code | Description |
|---|---|
| J7296 | Levonorgestrel-releasing intrauterine contraceptive system, (kyleena), 19.5 mg |
| J7297 | Levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg |
| J7301 | Levonorgestrel-releasing intrauterine contraceptive system (skyla), 13.5 mg |
| J7306 | Levonorgestrel (contraceptive) implant system, including implants and supplies |
| S4981 | Insertion of levonorgestrel-releasing intrauterine system |
Clinical
Clinical Trials
546 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 154 | 1 | — | 5 | 1 | 161 | ||
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 5 | 12 | 5 | 1 | — | 19 |
| Cataract | D002386 | EFO_0001059 | H26.9 | 1 | — | 1 | 9 | 2 | 13 |
| Infections | D007239 | EFO_0000544 | 5 | 1 | 3 | 1 | 1 | 11 | |
| Endophthalmitis | D009877 | 2 | 5 | 3 | 4 | — | 11 | ||
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 2 | 5 | 2 | 1 | 10 |
| Bacterial infections | D001424 | A49 | 3 | — | 1 | 4 | 1 | 9 | |
| Bacterial conjunctivitis | D003234 | EFO_1000829 | H10.0 | — | 1 | 4 | 3 | — | 8 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 4 | — | 2 | 1 | — | 7 |
| Chronic bronchitis | D029481 | J42 | — | — | 2 | 1 | 4 | 7 |
Show 33 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | — | 11 | 8 | — | 2 | 17 |
| Contraception | D003267 | 1 | 4 | 5 | — | 1 | 11 | ||
| Multidrug-resistant tuberculosis | D018088 | EFO_0007381 | — | 7 | 8 | — | — | 9 | |
| Community-acquired infections | D017714 | — | 2 | 3 | — | — | 5 | ||
| Lung diseases | D008171 | EFO_0003818 | J98.4 | 2 | 1 | 2 | — | — | 4 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | 2 | — | — | 4 |
| Extensively drug-resistant tuberculosis | D054908 | — | 4 | 4 | — | — | 4 | ||
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | — | 3 | — | — | 3 |
| Keratitis | D007634 | H16 | — | — | 3 | — | — | 3 | |
| Lymphoma | D008223 | C85.9 | 1 | — | 1 | — | 1 | 3 |
Show 36 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | 8 | 1 | — | — | — | 9 | ||
| Neoplasms | D009369 | C80 | 2 | 1 | — | — | 1 | 4 | |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 3 | 1 | — | — | — | 4 |
| Cholangitis | D002761 | K83.0 | — | 1 | — | — | — | 1 | |
| Corneal ulcer | D003320 | H16.0 | — | 1 | — | — | — | 1 | |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | — | — | — | 1 | |
| Meningeal tuberculosis | D014390 | A17.0 | — | 1 | — | — | — | 1 | |
| Graft vs host disease | D006086 | D89.81 | — | 1 | — | — | — | 1 | |
| Menorrhagia | D008595 | N92.0 | 1 | 1 | — | — | — | 1 | |
| Aplastic anemia | D000741 | HP_0001915 | D61.9 | 1 | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 6 | — | — | — | — | 6 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 3 | — | — | — | 1 | 4 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 4 | — | — | — | — | 4 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 4 | — | — | — | — | 4 |
| Asthma | D001249 | EFO_0000270 | J45 | 3 | — | — | — | — | 3 |
| Hepatitis c | D006526 | B19.2 | 3 | — | — | — | — | 3 | |
| Dyslipidemias | D050171 | HP_0003119 | 3 | — | — | — | — | 3 | |
| Therapeutic equivalency | D013810 | 3 | — | — | — | — | 3 | ||
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 2 | — | — | — | — | 2 |
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | 1 | — | — | — | 1 | 2 |
Show 49 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Long qt syndrome | D008133 | HP_0001657 | I45.81 | — | — | — | — | 2 | 2 |
| Pathologic dilatation | D004108 | — | — | — | — | 2 | 2 | ||
| Keratoconus | D007640 | EFO_0004223 | H18.6 | — | — | — | — | 2 | 2 |
| Regeneration | D012038 | — | — | — | — | 2 | 2 | ||
| Peritonitis | D010538 | EFO_0008588 | K65 | — | — | — | — | 2 | 2 |
| Delirium | D003693 | R41.0 | — | — | — | — | 1 | 1 | |
| Mycoplasma pneumonia | D011019 | EFO_0007387 | J15.7 | — | — | — | — | 1 | 1 |
| Appendicitis | D001064 | EFO_0007149 | K37 | — | — | — | — | 1 | 1 |
| Chemical and drug induced liver injury | D056486 | — | — | — | — | 1 | 1 | ||
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | — | — | — | 1 | 1 |
Show 7 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | NORGESTREL |
| INN | norgestrel |
| Description | Norgestrel, sold under the brand name Ovral among others, is a progestin medication which is used in birth control pills and in menopausal hormone therapy. It is available both in combination with an estrogen and alone. It is taken by mouth.
|
| Classification | Small molecule |
| Drug class | estrogens; progestins |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C#CC1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC |
Identifiers
| PDB | — |
| CAS-ID | 6533-00-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2107797 |
| ChEBI ID | — |
| PubChem CID | 16051930 |
| DrugBank | DB09389 |
| UNII ID | 3J8Q1747Z2 (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,093 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cryselle, Low-ogestrel
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
873 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more